Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
3.500
-0.080 (-2.23%)
At close: Nov 18, 2025, 4:00 PM EST
3.481
-0.019 (-0.55%)
After-hours: Nov 18, 2025, 5:29 PM EST
Anavex Life Sciences Employees
Anavex Life Sciences had 42 employees as of September 30, 2024. The number of employees increased by 2 or 5.00% compared to the previous year.
Employees
42
Change (1Y)
2
Growth (1Y)
5.00%
Revenue / Employee
n/a
Profits / Employee
-$1,146,905
Market Cap
300.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 42 | 2 | 5.00% |
| Sep 30, 2023 | 40 | 2 | 5.26% |
| Sep 30, 2022 | 38 | 13 | 52.00% |
| Sep 30, 2021 | 25 | 5 | 25.00% |
| Sep 30, 2020 | 20 | 4 | 25.00% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AVXL News
- 10 hours ago - Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 - GlobeNewsWire
- 4 days ago - Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease - GlobeNewsWire
- 20 days ago - Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group - GlobeNewsWire
- 5 weeks ago - Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care' - GlobeNewsWire
- 6 weeks ago - Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia - Seeking Alpha
- 6 weeks ago - Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program - GlobeNewsWire
- 6 weeks ago - Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - GlobeNewsWire
- 7 weeks ago - Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial - GlobeNewsWire